Table 4.
Budget impact analysis of PCV13 stratified by policy types: (A) Passive policy (B) Active policy.
| A. Passive policy | ||||||
|---|---|---|---|---|---|---|
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | Total |
| Total patients | 8,185,581 | 696,159 | 725,731 | 793,299 | 833,138 | 11,233,908 |
| Total eligible (exclude previous vaccination) | 7,776,302 | 661,351 | 689,444 | 753,634 | 791,481 | |
| Number of populations with acceptance | 3,888,151 | 330,676 | 344,722 | 376,817 | 395,741 | |
| Vaccine access rate (%) | 0.20 | 0.30 | 0.40 | 0.50 | 0.60 | |
| Number of accessible population with acceptance | 777,630 | 99,203 | 137,889 | 188,409 | 237,444 | 1,440,575 (vaccine coverage of 13, 25% including previous vaccination) |
| PCV13 full price (64.71 USD) | ||||||
| Total budget (USD) | 50,318,235 | 6,419,121 | 8,922,397 | 12,191,378 | 15,364,346 | 93,215,478 Average per year (18,643,096) |
| PCV13 reduced price (40.76 USD) | ||||||
| Total budget (USD) | 31,698,616.01 | 4,043,807.67 | 5,620,778.37 | 7,680,114.70 | 9,678,966.54 | 58,722,283 Average per year (11,744,457) |
| PCV13 reduced price (59.04 USD) | ||||||
| Total budget (USD) | 45,909,059.60 | 5,856,640.78 | 8,140,565.15 | 11,123,098.98 | 14,018,033.21 | 85,047,398 Average per year (17,009,480) |
| PPSV23 full price (29.44 USD) | ||||||
| Total budget (USD) | 22,895,577 | 2,920,800 | 4,059,829 | 5,547,266 | 6,991,016 | 42,414,488.40 Average per year (8,482,898) |
| B. Active policy | ||||||
|---|---|---|---|---|---|---|
| Year | 2022 | 2023 | 2024 | 2025 | 2026 | total |
| Total patients | 8,185,581 | 7,694,831 | 6,939,307 | 6,067,172 | 5,155,998 | 11,233,908 |
| Total eligible (exclude previous vaccination) | 7,776,302 | 7,310,089 | 6,592,341 | 5,763,814 | 4,898,198 | |
| Number of populations with acceptance | 3,888,151 | 3,655,045 | 3,296,171 | 2,881,907 | 2,449,099 | |
| Vaccine access rate (%) | 0.20 | 0.30 | 0.40 | 0.50 | 0.60 | |
| Number of accessible populations with acceptance | 777,630 | 1,096,513 | 1,318,468 | 1,440,953 | 1,469,459 | 6,103,025 (vaccine coverage of 54, 77% including previous vaccination) |
| PCV13 full price (64.71 USD) | ||||||
| Total budget (USD) | 50,318,235 | 70,952,258 | 85,314,328 | 93,239,990 | 95,084,537 | 394,909,348 Average per year (78,981,870) |
| PCV13 reduced price (40.76 USD) | ||||||
| Total budget (USD) | 31,698,616.01 | 44,697,282.71 | 53,744,852.75 | 58,737,724.81 | 59,899,721.25 | 248,778,198 Average per year (49,755,640) |
| PCV13 reduced price (59.04 USD) | ||||||
| Total budget (USD) | 45,909,059.60 | 64,735,009.72 | 77,838,592.29 | 85,069,761.65 | 86,752,679.42 | 360,305,103 Average per year (72,061,021) |
| PPSV23 full price (29.44 USD) | ||||||
| Total budget (USD) | 22,895,577 | 32,284,378 | 38,819,343 | 42,425,642 | 43,264,939 | 179,689,879 Average per year (35,937,976) |